Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alnylam Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Alnylam Announces New Management Appointments
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.